Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous hematopoietic stem cell transplant
- Development stage
- Phase 2
- Lead developer
- University Health Network
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This experimental cell therapy approach, evaluated in the ASCOTT (Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance) trial, aims to induce immune tolerance in liver transplant recipients. Led by Dr. Gary Levy at the University Health Network and Dr. Harold Atkins at The Ottawa Hospital, the procedure involves the collection of a patient's own CD34+ hematopoietic stem cells (HSCs) followed by a conditioning regimen of immune ablation using busulfan, cyclophosphamide, and rabbit anti-thymocyte globulin (ATG). The cryopreserved autologous stem cells are then reinfused to rebuild and "re-educate" the recipient's immune system. The primary therapeutic goal is to delete alloreactive T cell clones and promote the expansion of regulatory T cells (Tregs), thereby establishing operational tolerance to the transplanted liver and eliminating the need for lifelong immunosuppressive medications.
- Other names
- Autologous HSCTASCOTT trial therapyCD34+ hematopoietic stem cell transplant
Beyond the preview
Go deeper on autologous hematopoietic stem cell transplant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous hematopoietic stem cell transplant.